Unity Biotechnology, Inc. (UBX)
NASDAQ: UBX · IEX Real-Time Price · USD
1.500
+0.020 (1.35%)
At close: Apr 26, 2024, 4:00 PM
1.520
+0.020 (1.33%)
After-hours: Apr 26, 2024, 5:50 PM EDT
Unity Biotechnology Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
25.18M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 236.00K | -4.55M | -95.07% |
Dec 31, 2021 | 4.78M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Concord Medical Services Holdings | 75.80M |
Exagen | 52.55M |
Cumberland Pharmaceuticals | 39.55M |
Sol-Gel Technologies | 1.55M |
Oncternal Therapeutics | 785.00K |
Lipocine | -2.85M |
UBX News
- 2 days ago - UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting - GlobeNewsWire
- 4 days ago - UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME - GlobeNewsWire
- 12 days ago - UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates - GlobeNewsWire
- 2 months ago - New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss - GlobeNewsWire
- 4 months ago - UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME - GlobeNewsWire
- 5 months ago - UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates - GlobeNewsWire
- 6 months ago - UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds - GlobeNewsWire
- 7 months ago - UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration - GlobeNewsWire